Prostate cancer (PCa) remains a major health burden in men, being the second most common non-skin cancer and the fifth leading cause of death from cancer worldwide. Despite the use of serum prostate-specific antigen (PSA) as an important clinical tool for early PCa detection, this test has many shortcomings and has limited prognostic value. Therefore, there is a need of more reliable diagnostic markers to complement PSA, as well as better prognostic markers to differentiate aggressive from indolent tumors.
